Market Outlook

By 2032, the U.S. Peripheral Intravenous Catheters Market is projected to reach USD 4.31 billion, expanding at a compound annual growth rate of 7.80% across the forecast period from 2027 through 2032. The market valuation was recorded at USD 2.75 billion in 2026, following historical revenue benchmarks of USD 2.20 billion in 2023, USD 2.37 billion in 2024, and USD 2.55 billion in 2025. All monetary figures within this analysis are stated in USD billions.

The peripheral intravenous catheter space occupies a uniquely foundational role within American healthcare delivery. It represents the single most frequently executed invasive clinical procedure across the care continuum. More than 300 million peripheral intravenous catheters are placed across domestic healthcare settings each year, serving as the indispensable conduit for fluid resuscitation, transfusion therapy, intravenous pharmacotherapy, contrast administration, and blood sampling. Approximately 70% to 80% of all hospitalized patients in the United States receive at least one vascular access device during their inpatient stay, establishing peripheral catheters as the primary operational gateway for modern hospital medicine, critical care, and ambulatory surgery.

Demand within this sector is sustained by structural clinical forces, including demographic aging, rising surgical volumes, expanding chronic disease management protocols, and heightened inpatient acuity. In 2024, the volume of surgical admissions, emergency department attendances, and outpatient procedural encounters across the domestic health infrastructure continued to expand, placing immense operational stress on acute bedside workflows. Concurrently, clinical complication rates associated with peripheral vascular access remain a substantial clinical burden. Inpatient data indicate that between 35% and 50% of conventional peripheral intravenous catheters fail prematurely due to phlebitis, infiltration, occlusion, dislodgement, leakage, or local infection before intravenous therapy is successfully concluded.

This premature failure rate translates into an enormous operational, clinical, and financial drain across U.S. health systems. Each unexpected peripheral intravenous failure demands secondary venipunctures, increases patient discomfort, consumes nursing labor, delays essential pharmaceutical administration, and elevates the downstream risk of catheter-related bloodstream infections. In response, value analysis committees, nurse executive councils, and hospital procurement boards are aggressively pivoting away from commodity catheters toward advanced safety-engineered, integrated closed systems, blood-control technologies, and extended-dwell midline alternatives that protect vessel health, suppress accidental needle-stick injuries, and secure first-stick success.

The market is simultaneously experiencing a profound operational shift from episodic, reactive cannulation toward standardized, protocolized vessel health and preservation models. Ultrasound guidance, passive needle-retraction engineering, multi-access blood control valves, integrated stabilization platforms, and hemocompatible biomaterials such as advanced aliphatic polyurethanes are systematically replacing basic open-hub catheters. Manufacturers that couple high-performance vascular access devices with integrated needle-free connectors, specialized securement solutions, digital vein-visualization technologies, clinical education programs, and contract optimization within integrated delivery networks are consolidating distinct structural advantages across the commercial landscape.

Historical revenue expansion from 2023 to 2025 was propelled by post-pandemic procedural recovery, normal surgical cadence restoration, and the aggressive implementation of revised vascular access guidelines established by the Infusion Nurses Society and the Centers for Disease Control and Prevention. From 2027 onward, market acceleration will be predominantly governed by the widespread clinical migration toward fully closed integrated safety catheters, rapid conversion to extended-dwell devices in acute and post-acute wards, the clinical necessity to manage difficult intravenous access patient populations, and heightened regulatory mandates surrounding healthcare worker protection from bloodborne pathogens.

Introduction

The peripheral intravenous catheter segment represents an essential core of the American medical supplies and consumable device industry. Peripheral vascular access touches virtually every clinical touchpoint across the patient journey. A patient may enter an emergency department requiring rapid, large-bore fluid resuscitation, transition to an intensive care unit or surgical theater for anesthetic induction, step down to an inpatient med-surg unit for multi-day antibiotic therapy, and eventually discharge to home infusion or skilled nursing care with an extended-dwell peripheral catheter. This expansive utilization footprint transforms peripheral intravenous access into a high-frequency, indispensable recurring revenue pool characterized by inelastic clinical demand.

Safety-engineered peripheral intravenous catheters constitute the dominant revenue generator within the product landscape, accounting for approximately 64.7% of total U.S. peripheral intravenous catheter revenue in 2025. This commanding market share is the direct result of strict federal occupational mandates, primarily the Occupational Safety and Health Administration Bloodborne Pathogens Standard and the Needlestick Safety and Prevention Act. These regulatory frameworks established an enforceable legal obligation for healthcare facilities to implement engineered sharps injury protections. The economic architecture of safety catheters is particularly attractive to medtech vendors because safety-engineered mechanisms and passive needle shields command significant price premiums over non-safety conventional alternatives while maintaining massive unit replenishment volume.

Hospitals and integrated delivery networks represent the primary purchasing channel within the domestic landscape. Acute care institutions generate approximately 68.4% of total U.S. peripheral intravenous catheter expenditure, driven by high patient turnover, high therapeutic acuity, complex surgical schedules, and aggressive medication administration protocols. Inpatient environments require extensive inventories of varying catheter gauges, lengths, and configurations, spanning ultra-fine 24-gauge units for neonatal intensive care to high-flow 14-gauge configurations for adult trauma resuscitations. While hospital systems dominate overall market spending, outpatient environments such as ambulatory surgery centers, urgent care networks, and home infusion agencies represent faster-growing volume channels as complex care migrates outside the hospital.

The clinical and operational economics of peripheral vascular access diverge markedly from standard hospital commodity purchasing. Health systems are no longer evaluating catheters based purely on per-unit acquisition cost. Procurement officers, value analysis committees, and clinical specialists are comprehensively assessing the total cost of ownership. This calculation encompasses initial catheter acquisition expense alongside primary failure rates, secondary cannulation nursing hours, emergency vascular access team callouts, vein depletion complications, length-of-stay extensions, and the immense financial penalties tied to hospital-acquired catheter-related bloodstream infections under the Centers for Medicare and Medicaid Services Hospital-Acquired Condition Reduction Program. A five-dollar premium on an advanced integrated closed catheter is easily justified if it prevents a secondary insertion procedure, averts nurse turnover, and eliminates extravasation risks.

Ambulatory and home infusion care presents an entirely distinct procurement dynamic. The explosive expansion of outpatient parenteral antimicrobial therapy, specialty biologic infusions, and total parenteral nutrition has shifted vascular access demand toward durable devices that can dwell safely for days or weeks without replacement. In these non-acute environments, catheter failure triggers expensive emergency room transfers, disruption of expensive biologic regimens, and significant administrative overhead. Consequently, home infusion providers increasingly favor extended-dwell polyurethane catheters engineered to deliver prolonged patency and minimize thrombotic occlusions.

Regulatory compliance and occupational risk mitigation continue to serve as strong commercial catalysts across the country. Accidental percutaneous needlestick injuries expose clinical personnel to human immunodeficiency virus, hepatitis B, and hepatitis C, carrying direct testing, prophylaxis, and litigation costs that range from thousands to tens of thousands of dollars per incident. Devices incorporating automated passive safety shielding and integrated blood-containment septums provide measurable occupational risk reductions. These features are driving widespread clinical adoption across university medical centers and community health networks alike.

From 2027 through 2032, market leadership will be captured by medical technology enterprises that pivot away from selling standalone plastic cannulas and instead deliver integrated vascular access ecosystems. These advanced systems seamlessly unify passive safety needles, blood-control valves, integrated extension tubing, advanced catheter securement devices, and skin-friendly dressing interfaces into a sterile, single-step delivery vehicle. Manufacturers executing on this integrated paradigm are directly addressing the twin systemic crises of nursing shortages and clinical variability, cementing durable, high-margin, multi-year supply contracts across the domestic healthcare terrain.

Key Market Drivers: What’s Fueling the U.S. Peripheral Intravenous Catheters Market Boom?

The primary operational driver propelling the U.S. peripheral intravenous catheter market is the relentless volume of annual inpatient admissions, emergency department encounters, and surgical procedures occurring across an aging and medically complex population. Each year, the domestic healthcare system conducts tens of millions of major inpatient surgeries, outpatient ambulatory procedures, and emergency resuscitations, nearly all of which require immediate peripheral vascular cannulation. Concurrently, the rising prevalence of multiple chronic co-morbidities, including diabetes, chronic kidney disease, congestive heart failure, and obesity, has drastically complicated the vascular architecture of the modern patient. These clinical profiles frequently result in fragile, sclerosed, or non-visible peripheral vessels, dramatically increasing the complexity of standard cannulation.

A second critical driver is the acute clinical focus on managing difficult intravenous access patient populations. Clinical studies within U.S. acute care facilities establish that up to 35% of adult emergency patients and more than 40% of pediatric admissions exhibit clinical markers of difficult access. In these complex cohorts, conventional blind palpation cannulation results in high failure rates, requiring an average of 2.5 to 4 venipuncture attempts per successful placement. Multiple insertion attempts cause severe pain, escalate mechanical vessel trauma, destroy peripheral vascular capital, and severely delay life-saving pharmaceutical delivery. This reality has catalyzed rapid capital procurement of integrated vascular access programs, encompassing ultrasound-guided long-catheters, specialized thin-walled echogenic safety needles, and extended-length peripheral catheters engineered to access deeper, higher-caliber veins within the forearm and upper arm.

A third major driver is the accelerating clinical shift toward integrated closed catheter systems and blood-control technologies. Historical open-hub intravenous cannulation exposes the insertion site and the surrounding clinical environment to blood leakage upon stylet extraction, creating significant biohazard exposure for healthcare workers and contaminating the sterile field. Advanced integrated closed catheters resolve this vulnerability by incorporating pre-attached extension tubing, continuous multi-use blood control septums, and integrated stabilization platforms. By permanently sealing the blood pathway and eliminating repeated manipulation at the catheter hub, these platforms have demonstrated reductions in catheter manipulation-induced mechanical phlebitis and lower rates of external microbial contamination, driving enthusiastic endorsement from hospital infection prevention teams.

A fourth market driver stems from the sweeping adoption of clinical practice recommendations published by authoritative regulatory and professional bodies, specifically the Infusion Nurses Society Standards of Practice and updated guidelines from the Centers for Disease Control and Prevention. Historical hospital protocols mandated the routine replacement of peripheral intravenous catheters every 72 to 96 hours regardless of clinical necessity, driving unnecessary catheter consumption, repetitive vascular trauma, and inflated nursing workload. Current clinical consensus firmly mandates clinically indicated catheter removal, wherein a peripheral catheter remains in situ indefinitely until therapy completes or an overt clinical complication arises. This protocol shift has radically transformed the purchasing criteria of health systems. Rather than procuring high volumes of cheap, short-lived conventional catheters, hospital procurement committees are actively investing in premium polyurethane catheters and extended-dwell devices capable of maintaining vascular patency and endothelially safe dwell times extending from 7 to 29 days.

A fifth driver is the intensifying economic pressure created by acute nursing shortages and escalating clinical labor costs across U.S. hospitals. The American healthcare sector faces severe deficits in experienced bedside nurses, operating room technicians, and vascular access specialists. When a peripheral catheter fails unexpectedly, it forces bedside nurses to spend 30 to 45 minutes re-establishing access, diverting precious labor hours away from core patient monitoring and critical clinical tasks. Health systems are increasingly recognizing that deploying premium, high-success catheters equipped with instant flashback verification, ultra-sharp atraumatic needle bevels, and integrated securement represents a cost-effective strategy to compress insertion times, achieve high first-stick placement rates, and preserve nursing workforce efficiency.

A sixth driver is the institutional alignment with value-based healthcare reimbursement and strict quality metrics enforced by the Centers for Medicare and Medicaid Services. Under the Hospital-Acquired Condition Reduction Program, the Hospital Inpatient Quality Reporting framework, and the Hospital Readmissions Reduction Program, hospitals face heavy financial penalties for preventable clinical complications, local insertion infections, and vascular trauma leading to extended hospital stays. The total clinical management of a severe catheter-related bloodstream infection can easily exceed USD 0.045 billion across an enterprise network, dwarfing the per-unit price difference between standard and premium vascular access devices. Consequently, clinical executives are utilizing safety-engineered, closed-system catheters as an essential procedural barrier against hospital-acquired complications.

A seventh driver involves the significant expansion of outpatient and home-based infusion therapy models. Advanced biologics, subcutaneous immunoglobulins, specialized oncology regimens, intravenous iron therapies, and parenteral nutrition formulations are increasingly administered within specialized ambulatory infusion suites and patient residences. Patients managed in home care require robust, long-lasting peripheral access to avoid traumatic disruptions and emergency hospital transfers. Extended-dwell peripheral catheters and high-grade safety devices provide an ideal bridge between basic, short-term cannulas and invasive central venous access devices such as peripherally inserted central catheters, driving rapid unit expansion throughout non-acute distributor channels.

Finally, the expanding implementation of enterprise-wide group purchasing organization agreements and integrated delivery network standardization initiatives is consolidating purchasing power and accelerating technology diffusion. Multi-facility health networks are systematically eliminating fragmented purchasing practices, replacing hospital-by-hospital brand selections with system-wide supply contracts. In these high-stakes enterprise negotiations, manufacturers offering complete, comprehensive vascular access portfolios spanning peripheral safety catheters, midlines, ultrasonic tip-location devices, securement dressings, and clinical training programs are capturing market share over isolated niche hardware manufacturers.

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation across the U.S. peripheral intravenous catheter arena is centered on solving the pervasive clinical challenges of premature mechanical failure, blood exposure, vessel trauma, and multi-stick insertion failure. Market leaders are no longer competing strictly on needle grind angles or polymer wall thickness. Instead, competitive advantage is defined by advanced material science, closed-system fluidics, needle-tip design, passive safety automation, and digital visualization integration.

Biomaterial engineering represents a critical domain of recent breakthroughs. Historical peripheral catheters were largely extruded from fluorinated ethylene propylene, a stiff polymer that facilitates easy initial skin penetration but remains rigid inside the vein, resulting in mechanical irritation, endothelial trauma, and catheter kinking whenever the patient moves. Current innovation is centered on advanced thermosensitive aliphatic polyurethanes. These specialized biomaterials maintain sufficient structural column strength at room temperature to achieve smooth, resistance-free dermal and vascular insertion, but soften up to 70% once exposed to intravascular body temperature. This thermo-softening capability allows the catheter to conform naturally to the tortuous architecture of the venous lumen, dampening intimal vessel irritation, suppressing mechanical phlebitis, and reducing mechanical occlusions over prolonged dwell cycles.

Blood-control septum technology has emerged as another transformative product innovation. Traditional peripheral catheter insertion requires clinical operators to apply manual digital occlusion over the vein while withdrawing the metal introducer needle, an awkward technique that frequently fails and results in blood leaking onto patient bedding, clothing, and the clinician’s gloves. Next-generation safety catheters integrate multi-use, internal elastomeric blood-control valves directly within the catheter hub. These precision-engineered septums automatically seal the catheter lumen upon stylet retraction, completely containing blood flow within the device without requiring manual vein compression. Furthermore, these valves remain functional through multiple luer-lock connections and disconnections, permitting clean, closed-system administration of medications, flushes, and blood draws while maintaining zero occupational biohazard exposure.

Stylet design and early vascular visualization technologies have simultaneously elevated insertion success rates. A primary cause of peripheral catheter failure during insertion is the clinician prematurely advancing the flexible catheter before the cannula has fully entered the vein lumen, leading to catheter collapse or subcutaneous blowing of the vessel. Leading manufacturers have resolved this with proprietary dual-flashback and notch-needle technologies. By cutting a precision micro-notch or slot directly into the metal introducer needle near the bevel, blood immediately enters the clear catheter tubing the millisecond the needle tip enters the vessel, providing the clinician with instantaneous visual confirmation of vascular entry before blood even appears in the rear flashback chamber. This immediate visual feedback drastically increases first-stick success rates in hypotensive, pediatric, and elderly patients with low venous pressures.

Passive safety automation has permanently redefined sharps injury protection standards. Early-generation active safety catheters required the clinician to manually press a button, slide a plastic shield, or flick a lever to cover the contaminated needle after withdrawal, actions that were frequently skipped during chaotic emergency, surgical, or pediatric interventions. Advanced passive safety catheters entirely eliminate human compliance variables. As the needle is withdrawn from the catheter hub, an internal mechanical latch or self-activating spring clip automatically and irreversibly encapsulates the needle tip within a stainless-steel safety chamber, ensuring total occupational protection with zero modification to conventional clinical technique.

The convergence of peripheral catheters with engineered securement and integrated extension sets represents the pinnacle of modern vascular design. Conventional practices of taping unshielded catheter hubs directly to the patient’s skin allow micro-movements, pistoning, and accidental dislodgement, which severely compromise the vascular insertion site. Fully integrated closed catheter systems combine the safety catheter, an integrated polyurethane extension set, an elastomeric clamp, and a dual-port or split-septum access hub into a single, pre-assembled, sterile unit. By relocating all syringe connections away from the insertion site to the end of the extension line, these integrated platforms eliminate mechanical hub manipulation, dramatically reduce pistoning, and preserve the endothelial integrity of the vessel wall.

The clinical boundary between peripheral intravenous catheters and peripherally inserted central catheters is rapidly blurring due to the emergence of extended-dwell peripheral catheters and short midline systems. Historically, patients requiring intermediate intravenous therapy lasting between one and four weeks were subjected to invasive, expensive central line placements, carrying significant risks of pneumothorax, arterial puncture, and central line-associated bloodstream infections. Modern extended-dwell catheters, measuring between 3.0 and 8.0 centimeters in length, are inserted into deep veins of the upper arm utilizing direct ultrasound visualization and modified Seldinger techniques. These platforms provide reliable, high-flow vascular access for weeks without encroaching into the central venous system, saving thousands of dollars per patient encounter while avoiding central line infection registries.

Furthermore, catheter manufacturers are increasingly engineering specialized power-injectable peripheral systems. Historically, diagnostic computed tomography scans and magnetic resonance imaging requiring rapid, high-pressure administration of radiopaque contrast agents necessitated the placement of dedicated large-gauge lines or power-injectable central devices. Contemporary peripheral catheters are constructed with high-burst-pressure polyurethane formulations capable of withstanding dynamic pressures up to 300 to 325 pounds per square inch and fluid flow rates exceeding 10 milliliters per second. This enables emergency and diagnostic departments to utilize a single pre-existing peripheral catheter for both routine medication administration and high-pressure imaging procedures, streamlining hospital throughput and eliminating duplicate venipunctures.

Segmentation Insights

The U.S. Peripheral Intravenous Catheters Market is segmented based on Product Type, Catheter Material, Technology and Design Mechanism, End User, Clinical Application, and Geography.

By Product Type

The Product Type segmentation comprises Safety Peripheral Intravenous Catheters, Conventional and Standard Peripheral Intravenous Catheters, Integrated and Closed Peripheral Intravenous Catheter Systems, and Extended Dwell and Midline Peripheral Catheters. The entire product ecosystem is undergoing rapid technological premiumization, with market revenue transitioning systematically from open, basic designs toward engineered closed-system and extended-dwell architectures.

• Safety Peripheral Intravenous Catheters represent the largest single revenue contributor across the domestic product landscape, generating USD 1.78 billion in 2026, up from historical benchmarks of USD 1.43 billion in 2023, USD 1.54 billion in 2024, and USD 1.66 billion in 2025. This segment is forecast to achieve a valuation of USD 2.76 billion by 2032, expanding at a robust compound annual growth rate of 7.58% across the 2027 through 2032 forecast horizon. The commanding market scale of safety catheters is firmly anchored by statutory workplace mandates, institutional infection control protocols, and the universal clinical requirement to protect healthcare workers from percutaneous sharps injuries and bloodborne pathogen transmission. Safety catheters are segmented into active safety configurations, which require clinician manual activation, and passive safety configurations, which engage shielding mechanisms automatically upon stylet withdrawal. Health systems are aggressively prioritizing passive configurations to eradicate human compliance errors, establishing safety catheters as the non-negotiable procurement standard across acute inpatient hospitals, surgical suites, and emergency treatment networks throughout the United States.
• Conventional and Standard Peripheral Intravenous Catheters generated USD 0.28 billion in 2026, having recorded USD 0.25 billion in 2023, USD 0.26 billion in 2024, and USD 0.27 billion in 2025. This legacy category is projected to reach USD 0.33 billion by 2032, exhibiting a constrained compound annual growth rate of 2.78% from 2027 through 2032. Conventional catheters feature traditional open-hub designs lacking integrated needle shielding or blood-retention valves, leaving clinical operators vulnerable to accidental needlesticks and blood splashes. While these commodity devices have been largely eradicated from mainstream inpatient hospital systems due to stringent Occupational Safety and Health Administration regulations, they maintain a stable baseline of residual demand across specialized outpatient clinics, veterinary medicine, academic research laboratories, cost-sensitive private practices, and specific ambulatory facilities where procedural risk profiles and tight budgetary limitations preserve basic product procurement. However, unit volume within this segment is facing long-term structural displacement as safety-engineered designs become increasingly cost-competitive and mandatory across broader healthcare environments.
• Integrated and Closed Peripheral Intravenous Catheter Systems represent one of the most commercially dynamic and rapidly accelerating product classes, generating USD 0.47 billion in 2026, following historical revenue milestones of USD 0.35 billion in 2023, USD 0.39 billion in 2024, and USD 0.43 billion in 2025. This premium category is projected to expand to USD 0.82 billion by 2032, demonstrating a rapid compound annual growth rate of 9.73% across the forecast period. Integrated closed systems unify the peripheral catheter, an integrated needle protection mechanism, pre-attached extension tubing, an elastomeric fluid control clamp, and a dual-port luer access hub into a single, continuous, pre-assembled sterile device. This closed configuration completely prevents blood leakage during insertion, eliminates the risk of air embolism, and isolates the sensitive cannulation site from mechanical movement during line connections, reducing mechanical phlebitis, catheter-related bloodstream infections, and premature line failure. Clinical guidelines from the Infusion Nurses Society increasingly recommend closed catheter architectures, accelerating extensive enterprise-level conversions across intensive care units, emergency departments, and high-acuity surgical theaters.
• Extended Dwell and Midline Peripheral Catheters represent the fastest-growing product segment, recording USD 0.22 billion in 2026, up from USD 0.16 billion in 2023, USD 0.18 billion in 2024, and USD 0.20 billion in 2025. This advanced segment is forecast to reach USD 0.40 billion by 2032, advancing at an impressive compound annual growth rate of 10.51% between 2027 and 2032. Extended-dwell catheters typically measure between 3.0 and 8.0 centimeters in length, bridging the clinical gap between standard short peripheral cannulas and peripherally inserted central catheters. Constructed from advanced medical-grade polyurethanes, these devices are designed to dwell safely within deeper peripheral veins for periods extending from 7 to 29 days without requiring routine line changes. The explosive commercial adoption of extended-dwell catheters is driven by health systems seeking to avoid the high insertion costs, procedural complications, and central-line bloodstream infection risks associated with centrally placed lines. Furthermore, the rising volume of patients requiring multi-week outpatient antibiotic regimens, hydration therapies, and oncology support makes extended-dwell midlines an essential operational asset across both acute inpatient units and home infusion environments.

By Catheter Material

The Catheter Material segmentation evaluates the market across Polyurethane Catheters and Fluorinated Ethylene Propylene and Polytetrafluoroethylene Catheters. The material composition of a peripheral catheter directly governs its intravascular biocompatibility, mechanical kink resistance, insertion mechanics, and thrombogenic profile.

• Polyurethane Catheters dominate material category revenues, accounting for USD 1.95 billion in 2026, compared to historical milestones of USD 1.53 billion in 2023, USD 1.66 billion in 2024, and USD 1.80 billion in 2025. This advanced biomaterial segment is projected to achieve a market valuation of USD 3.16 billion by 2032, expanding at a compound annual growth rate of 8.38% from 2027 through 2032. Polyurethane is celebrated across the vascular access community for its thermo-softening properties, remaining rigid and structurally stable at room temperature to ensure clean, resistance-free dermal penetration, and subsequently softening within the vascular lumen upon exposure to human body temperature. This dramatic reduction in mechanical stiffness enables the catheter to bend smoothly within tortuous venous pathways, drastically minimizing mechanical irritation to the delicate vascular endothelium, reducing thrombophlebitis, preventing catheter kinking, and supporting extended in-dwelling times. Furthermore, advanced aliphatic polyurethanes demonstrate lower bacterial adhesion and platelet aggregation rates compared to older polymers, making polyurethane the indispensable gold standard for high-end safety catheters, integrated systems, and extended-dwell devices across U.S. hospital networks.
• Fluorinated Ethylene Propylene and Polytetrafluoroethylene Catheters generated USD 0.80 billion in 2026, following historical revenues of USD 0.67 billion in 2023, USD 0.71 billion in 2024, and USD 0.75 billion in 2025. This mature material category is anticipated to reach USD 1.15 billion by 2032, expanding at a moderate compound annual growth rate of 6.23% over the forecast period. Fluorinated ethylene propylene remains popular due to its high tensile strength, exceptional optical clarity, and low coefficient of surface friction, which provides clinicians with immediate, crisp flashback visualization and clean tactile feedback during initial venipuncture. However, fluorinated ethylene propylene is a rigid plastic that maintains its stiffness while in situ, making it significantly more prone to kinking, mechanical irritation, and premature failure if the catheter traverses a point of articulation or encounters venous spasm. While fluorinated ethylene propylene catheters continue to command high unit volumes within high-turnover clinical environments such as emergency triage, short-stay ambulatory surgery centers, and routine outpatient diagnostic clinics, premium healthcare facilities are progressively shifting their primary procurement budgets toward high-biocompatibility polyurethane formulations.

By Technology and Design Mechanism

The Technology and Design Mechanism segmentation categorizes the market into Retractable Needle Systems, Shielded and Encased Needle Systems, Blood Control and Flow-Restriction Septum Systems, and Integrated Stabilization and Engineered Securement Devices. These engineering mechanisms represent the core focal points for intellectual property, regulatory compliance, and clinical differentiation.

• Retractable Needle Systems generated USD 0.99 billion in 2026, having expanded from USD 0.80 billion in 2023, USD 0.86 billion in 2024, and USD 0.92 billion in 2025. This critical safety technology is projected to reach USD 1.54 billion by 2032, progressing at a compound annual growth rate of 7.64% across the 2027 through 2032 period. Retractable needle designs utilize internal spring-loaded mechanisms or manual retraction plungers that pull the contaminated needle completely back inside the barrel or catheter housing immediately upon venous cannulation. By isolating the sharp needle tip within an impenetrable plastic chamber before the device is fully separated from the patient’s skin, retraction systems effectively eliminate the hazard of accidental needlestick exposure during high-stress clinical procedures. These systems are heavily deployed across emergency medical services, trauma units, intensive care environments, and psychiatric facilities where patient movement and procedural urgency amplify occupational puncture risks.
• Shielded and Encased Needle Systems accounted for USD 0.91 billion in 2026, following historical performance of USD 0.74 billion in 2023, USD 0.79 billion in 2024, and USD 0.85 billion in 2025. This safety category is projected to reach USD 1.41 billion by 2032, reflecting a compound annual growth rate of 7.57% from 2027 to 2032. Unlike active retraction systems, shielded catheters utilize mechanical pass-through safety clips, metal shells, or folding plastic barriers that slide smoothly over the sharp needle point as the stylet is extracted from the hub, locking permanently into place to encapsulate the biohazardous tip. Shielded mechanisms can be engineered into compact, low-profile configurations that provide clinicians with unobstructed visualization of the insertion site, supporting traditional insertion angles and tactile techniques. Their robust mechanical reliability, low activation force, and exceptional manufacturing scalability make shielded safety catheters one of the most widely stocked SKUs across large hospital networks, surgical facilities, and ambulatory health systems nationwide.
• Blood Control and Flow-Restriction Septum Systems generated USD 0.52 billion in 2026, having recorded USD 0.40 billion in 2023, USD 0.44 billion in 2024, and USD 0.48 billion in 2025. This high-growth category is expected to achieve USD 0.86 billion by 2032, advancing at a rapid compound annual growth rate of 8.74% throughout the forecast horizon. Blood control technology incorporates an elastomeric micro-valve embedded directly within the catheter hub that prevents blood from escaping into the external environment once the needle is withdrawn, even before an infusion line or extension set is attached. This eliminates the messy blood leakage and splash risks that historically accompanied open-hub catheter insertions, protecting clinicians from bloodborne pathogen exposure and preventing contamination of patient linens and wound sites. By eliminating the necessity for clumsy manual digital venous occlusion during insertion, blood control systems streamline nursing workflows, conserve sterile drapes, and simplify cannulation in high-risk, anticoagulated, and hemodynamically unstable patients.
• Integrated Stabilization and Engineered Securement Devices accounted for USD 0.33 billion in 2026, up from historical levels of USD 0.26 billion in 2023, USD 0.28 billion in 2024, and USD 0.30 billion in 2025. This specialized design segment is forecast to achieve a valuation of USD 0.50 billion by 2032, expanding at a compound annual growth rate of 7.18% over the forecast timeframe. Catheter micro-motion, pistoning, and accidental dislodgement are primary contributors to endothelial trauma, peripheral vein loss, and secondary line contamination. Integrated stabilization designs feature built-in stabilization wings, contoured plastic platforms, and specialized adhesive interfaces engineered directly into the catheter hub architecture. By anchoring the device firmly to the dermal plane without requiring separate, bulky adhesive tapes or external plastic clips, integrated securement minimizes catheter movement inside the vessel, reduces the incidence of mechanical phlebitis, and supports the prolonged clinical dwell times required under modern vascular preservation protocols.

By End User

The End User segmentation delineates market consumption across Hospitals and Integrated Delivery Networks, Ambulatory Surgery Centers and Outpatient Clinics, Emergency Medical Services and Urgent Care Centers, and Home Infusion Therapy and Long-Term Care Facilities. Purchasing behavior across these distinct healthcare environments is shaped by clinical acuity, institutional patient throughput, reimbursement structures, and staffing models.

• Hospitals and Integrated Delivery Networks constitute the premier end-user channel, commanding USD 1.88 billion in 2026, following historical revenue milestones of USD 1.52 billion in 2023, USD 1.63 billion in 2024, and USD 1.75 billion in 2025. This central institutional segment is forecast to reach USD 2.91 billion by 2032, advancing at a compound annual growth rate of 7.57% across the 2027 through 2032 projection window. Inpatient health systems represent massive consumer bases for vascular access products, utilizing peripheral catheters across emergency departments, operating suites, intensive care units, labor and delivery wards, and general medical-surgical floors. Large health networks utilize enterprise-wide value analysis committees to negotiate consolidated group purchasing organization contracts, demanding premium safety-engineered catheters that deliver demonstrated reductions in secondary stick attempts, needle-stick injuries, and catheter-associated infections. With hospital operating margins facing intense pressure from nursing shortages and regulatory penalties, hospital leadership is aggressively investing in high-reliability, closed-system catheter platforms to optimize clinical labor and protect revenue streams.
• Ambulatory Surgery Centers and Outpatient Clinics generated USD 0.44 billion in 2026, having recorded USD 0.34 billion in 2023, USD 0.37 billion in 2024, and USD 0.40 billion in 2025. This expanding outpatient sector is projected to reach USD 0.72 billion by 2032, charting a rapid compound annual growth rate of 8.56% across the forecast period. The sweeping migration of elective orthopedic, cardiovascular, ophthalmic, and general surgical procedures from inpatient hospital suites into specialized ambulatory centers is generating massive demand for high-performance peripheral vascular access. In fast-paced ambulatory surgery environments, procedural efficiency, rapid turnaround times, and reliable first-stick cannulation are paramount. Clinicians prioritize ultra-sharp, low-profile safety catheters that facilitate rapid anesthetic induction and seamless fluid administration, allowing patients to recover smoothly and discharge on the same calendar day without vascular complications or intravenous site leakage.
• Emergency Medical Services and Urgent Care Centers accounted for USD 0.25 billion in 2026, following historical values of USD 0.20 billion in 2023, USD 0.21 billion in 2024, and USD 0.23 billion in 2025. This critical pre-hospital segment is anticipated to achieve USD 0.40 billion by 2032, growing at a compound annual growth rate of 8.16% from 2027 to 2032. Emergency medical personnel, paramedics, and urgent care practitioners routinely operate under uncontrolled, turbulent field environments where rapid vascular access is essential for patient survival. Pre-hospital providers require rugged, highly reliable safety catheters equipped with advanced blood containment, instant flashback visualization, and durable passive shielding that functions flawlessly regardless of lighting, environmental vibration, or patient combativeness. Furthermore, the explosive proliferation of private urgent care networks across suburban and urban corridors is diverting high volumes of acute, non-life-threatening medical cases away from crowded hospital emergency departments, creating an expansive, decentralized commercial channel for safety peripheral catheter replenishment.
• Home Infusion Therapy and Long-Term Care Facilities accounted for USD 0.18 billion in 2026, having risen from USD 0.14 billion in 2023, USD 0.15 billion in 2024, and USD 0.17 billion in 2025. This specialized sector is forecast to attain USD 0.28 billion by 2032, representing a compound annual growth rate of 7.64% across the forecast horizon. Driven by an aging population, rising rates of chronic degenerative disease, and payer incentives encouraging early hospital discharge, home infusion therapy has become an indispensable component of the domestic continuum of care. Patients receiving long-term intravenous antibiotics, parenteral nutrition, hydration, and biologic therapies in post-acute environments require vascular access devices that can dwell safely for prolonged intervals without occluding, leaking, or becoming dislodged. Home infusion nurses and skilled nursing staff heavily procure extended-dwell polyurethane catheters, integrated closed systems, and advanced securement dressings, as every line failure in a home environment necessitates expensive nursing dispatch visits or disruptive emergency department transfers.

By Clinical Application

The Clinical Application segmentation analyzes the utilization of peripheral catheters across General Inpatient and Surgical Infusion, Oncology and Chemotherapy Administration, Pediatric and Neonatal Vascular Access, and Critical Care, Trauma, and Emergency Medicine. Clinical demands within each specialty govern the gauge, length, material resilience, and engineering complexity of the required catheter configurations.

• General Inpatient and Surgical Infusion represents the largest clinical volume segment, accounting for USD 1.35 billion in 2026, compared to historical benchmarks of USD 1.10 billion in 2023, USD 1.18 billion in 2024, and USD 1.26 billion in 2025. This core clinical category is forecast to achieve a valuation of USD 2.08 billion by 2032, charting a compound annual growth rate of 7.46% between 2027 and 2032. General medical-surgical admissions, perioperative suites, post-anesthesia care units, and routine procedural wards utilize immense daily volumes of standard 18-, 20-, and 22-gauge peripheral catheters for continuous maintenance fluid hydration, pre-operative prophylactic antibiotic dosing, post-operative analgesic administration, and routine venous blood sampling. Hospital value analysis committees consistently target this segment for enterprise-wide catheter standardization initiatives, aiming to reduce SKU redundancy, negotiate volume rebates, and enforce institutional protocols that minimize premature line dislodgement and thrombophlebitis across routine inpatient floors.
• Oncology and Chemotherapy Administration accounted for USD 0.52 billion in 2026, following historical performance of USD 0.40 billion in 2023, USD 0.44 billion in 2024, and USD 0.48 billion in 2025. This critical specialty area is projected to reach USD 0.85 billion by 2032, demonstrating a rapid compound annual growth rate of 8.52% across the forecast horizon. Oncology patients represent an extraordinarily challenging vascular access population. Repeated cytotoxic drug infusions, chronic venipunctures, and immunosuppressive therapies cause severe peripheral vein sclerosis, vessel fragility, and hyper-reactivity. Extravasation of vesicant chemotherapeutic agents into subcutaneous tissue causes severe tissue necrosis, requiring immediate, highly reliable vascular placement. Consequently, oncology infusion centers heavily utilize closed-system integrated safety catheters, blood-control devices, and extended-dwell polyurethane lines that maintain exceptional seal integrity, prevent cytotoxic drug leakage, and protect vulnerable peripheral vessel pathways throughout cyclical cancer therapies.
• Pediatric and Neonatal Vascular Access generated USD 0.30 billion in 2026, having expanded from historical figures of USD 0.23 billion in 2023, USD 0.25 billion in 2024, and USD 0.27 billion in 2025. This highly delicate application segment is projected to achieve a market value of USD 0.49 billion by 2032, expanding at a compound annual growth rate of 8.52% from 2027 through 2032. Cannulating pediatric and neonatal patients requires exceptional technical precision, as tiny, fragile veins are obscured by infant subcutaneous fat and highly prone to collapse or rupture. Manufacturers engineer specialized ultra-fine 24- and 26-gauge catheters equipped with micro-notched needles that provide instantaneous capillary flashback visualization, allowing pediatric clinicians to halt needle advancement the exact millisecond the vein lumen is engaged. Furthermore, pediatric hospitals require ultra-soft polyurethane materials, low-profile hubs, and specialized integrated securement wings to prevent catheter migration caused by unavoidable infant limb movement, reducing traumatic re-stick procedures in specialized pediatric wards.
• Critical Care, Trauma, and Emergency Medicine accounted for USD 0.58 billion in 2026, up from historical levels of USD 0.47 billion in 2023, USD 0.50 billion in 2024, and USD 0.54 billion in 2025. This intensive clinical segment is anticipated to attain USD 0.89 billion by 2032, advancing at a compound annual growth rate of 7.40% over the forecast period. In emergency departments, level-one trauma centers, and intensive care units, clinicians routinely manage hemodynamically collapsed patients requiring massive, rapid fluid resuscitation, whole-blood transfusions, and emergent intravenous pharmacotherapy. These critical environments require high-flow, large-bore 14- and 16-gauge catheters constructed with reinforced, kink-resistant polyurethane walls capable of handling high volumetric flow rates without collapsing. Furthermore, emergency and trauma practitioners heavily demand power-injectable peripheral catheters compatible with automated computed tomography contrast injectors, allowing rapid diagnostic trauma scans without subjecting unstable emergency patients to secondary vascular line insertions.

Regional Insights: Where the Market is Growing Fastest

The U.S. Peripheral Intravenous Catheters Market is segmented into four primary geographic regions: the South, the Northeast, the Midwest, and the West. Regional demand dynamics are shaped by demographic concentration, population migration trends, regional disease prevalence, hospital and ambulatory facility density, group purchasing organization penetration, state-level occupational safety enforcement, and health system capital infrastructure investments.

The South constitutes the largest overall commercial marketplace for peripheral intravenous catheters, driven by its massive population base, rapid demographic growth, high concentration of hospital beds, and extensive senior citizen Medicare populations. Conversely, the West represents the fastest-growing regional market, propelled by rapid technological modernization, high penetration of outpatient ambulatory surgical networks, and aggressive clinical adoption of integrated closed safety platforms. The Northeast remains a premier high-value territory characterized by the nation’s highest concentration of elite academic medical centers and clinical research networks, while the Midwest combines massive industrial healthcare networks, mature integrated delivery networks, and expansive community hospital systems managing substantial chronic disease cohorts.

South

The South represents the premier regional market for peripheral intravenous catheters in the United States, generating USD 1.05 billion in 2026, following historical performance of USD 0.83 billion in 2023, USD 0.90 billion in 2024, and USD 0.97 billion in 2025. The region is forecast to achieve a market size of USD 1.66 billion by 2032, advancing at a compound annual growth rate of 7.93% throughout the forecast horizon. The South’s commercial dominance is firmly anchored in its substantial demographic scale, rapid population influx, high surgical procedural volumes, and an immense concentration of inpatient healthcare facilities. Furthermore, the southern states exhibit higher regional rates of chronic cardiovascular disease, diabetes, obesity, and end-stage renal disease compared to national averages, conditions that systematically erode vascular health and translate into elevated inpatient admissions and high peripheral catheter utilization rates.

Texas serves as the cornerstone state market within the South and represents the second-largest individual state market in the United States. In 2026, the Texas peripheral intravenous catheter market was valued at USD 0.31 billion, having expanded from USD 0.24 billion in 2023, USD 0.26 billion in 2024, and USD 0.28 billion in 2025. The state is projected to reach USD 0.50 billion by 2032, expanding at an aggressive compound annual growth rate of 8.28% between 2027 and 2032. Texas possesses an expansive healthcare infrastructure anchored by major metropolitan health systems in Houston, Dallas-Fort Worth, San Antonio, and Austin, including the Texas Medical Center, the largest medical complex in the world. Texas hospitals conduct immense volumes of inpatient surgeries, organ transplantations, and emergency resuscitations, consuming tens of millions of peripheral catheters annually. Furthermore, rapid corporate and residential migration into Texas is fueling an unprecedented construction boom in ambulatory surgery centers, freestanding emergency departments, and suburban urgent care facilities, driving sustained, high-volume procurement of premium safety-engineered and integrated closed catheter platforms.

Florida represents an exceptionally lucrative state market, generating USD 0.26 billion in 2026, following historical revenue milestones of USD 0.20 billion in 2023, USD 0.22 billion in 2024, and USD 0.24 billion in 2025. The Florida market is forecast to reach USD 0.42 billion by 2032, charting a compound annual growth rate of 8.33% across the forecast period. Florida’s market profile is uniquely shaped by its massive retiree and senior citizen demographic, resulting in an exceptionally high concentration of Medicare beneficiaries. Older patients frequently present with delicate, fragile, and tortuous peripheral veins, drastically escalating the incidence of difficult intravenous access and mechanical vein collapse. Consequently, Florida hospitals, long-term acute care facilities, and home healthcare networks heavily procure thermo-softening polyurethane catheters, specialized micro-notch pediatric/geriatric needles, and extended-dwell midlines. Regional integrated delivery networks across Orlando, Tampa, Miami, and Jacksonville are aggressively standardizing on closed-system catheters to suppress catheter failure rates and protect patient vessel capital.

North Carolina represents a major southeastern medical technology hub, recording USD 0.11 billion in 2026, up from USD 0.09 billion in 2023, USD 0.10 billion in 2024, and USD 0.10 billion in 2025. The state is projected to achieve USD 0.18 billion by 2032, registering a compound annual growth rate of 8.52% throughout the forecast horizon. North Carolina’s vascular access market is anchored by prestigious academic healthcare systems and extensive health networks spanning Charlotte, Raleigh, Durham, and Winston-Salem, such as Duke Health, UNC Health, and Atrium Health. These sophisticated institutions serve as early clinical adopters of advanced vascular access technologies, aggressively implementing comprehensive vascular preservation protocols that leverage ultrasound-guided long peripheral catheters, power-injectable safety devices, and integrated stabilization systems.

Georgia accounted for USD 0.10 billion in 2026, following historical revenues of USD 0.08 billion in 2023, USD 0.09 billion in 2024, and USD 0.09 billion in 2025. The Georgia market is anticipated to reach USD 0.16 billion by 2032, progressing at a compound annual growth rate of 8.16% over the forecast timeframe. The state’s commercial demand is heavily concentrated across the greater Atlanta metropolitan area, home to massive regional trauma centers, specialized pediatric health networks, and expanding ambulatory surgical complexes. Georgia’s extensive network of rural community hospitals, combined with its high-volume urban safety-net systems, creates diverse procurement patterns spanning both cost-efficient shielded safety catheters and high-end integrated closed systems designed to minimize nursing workload.

The remainder of the southern territory encompasses Tennessee, Virginia, Maryland, Louisiana, Alabama, South Carolina, Kentucky, Oklahoma, Arkansas, Mississippi, West Virginia, and Delaware, collectively representing USD 0.27 billion in 2026 and forecast to achieve USD 0.40 billion by 2032, growing at a compound annual growth rate of 6.79%. States such as Tennessee and Virginia maintain prominent medical centers in Nashville, Memphis, Richmond, and Norfolk, driving substantial clinical demand. Conversely, rural regions across Mississippi, Alabama, and West Virginia grapple with severe chronic disease burdens and hospital operating margin constraints, creating high demand for reliable, cost-effective safety catheters that satisfy federal occupational safety mandates while maximizing procedural budget efficiency.

Northeast

The Northeast represents the most clinically sophisticated and high-value regional market for peripheral intravenous catheters, generating USD 0.58 billion in 2026, after recording USD 0.47 billion in 2023, USD 0.50 billion in 2024, and USD 0.54 billion in 2025. The Northeast is projected to achieve a market size of USD 0.88 billion by 2032, expanding at a compound annual growth rate of 7.21% across the 2027 through 2032 forecast horizon. The Northeast is characterized by an unparalleled concentration of world-renowned academic medical centers, elite university teaching hospitals, specialized cancer research institutes, and dense urban hospital systems. Inpatient care in this region is defined by exceptionally high clinical acuity, advanced surgical specialization, and rigorous evidence-based nursing protocols. Healthcare executives and value analysis committees in the Northeast place intense emphasis on clinical outcome data, infection reduction metrics, and advanced nursing education, creating an extraordinarily fertile commercial landscape for premium integrated closed catheters and extended-dwell devices.

New York serves as the dominant state market in the Northeast and the third-largest state market nationally, generating USD 0.22 billion in 2026, following historical revenues of USD 0.18 billion in 2023, USD 0.19 billion in 2024, and USD 0.21 billion in 2025. The New York market is projected to reach USD 0.33 billion by 2032, expanding at a compound annual growth rate of 6.99% across the forecast period. The state’s market is anchored by the massive New York City metropolitan healthcare complex, which includes some of the largest public and private health networks in the country, such as New York-Presbyterian, Mount Sinai, NYU Langone, and NYC Health + Hospitals, alongside major regional networks across Long Island and upstate New York. These massive institutions manage immense daily patient volumes across high-density emergency departments, critical care units, and specialized oncology centers. New York healthcare providers enforce stringent occupational safety guidelines and have been at the forefront of implementing needle-free closed systems and passive safety-engineered catheters to protect clinical staff from bloodborne pathogen exposure in fast-paced clinical environments.

Pennsylvania represents the second-largest state market within the Northeast, valued at USD 0.14 billion in 2026, up from historical levels of USD 0.11 billion in 2023, USD 0.12 billion in 2024, and USD 0.13 billion in 2025. The state is forecast to achieve USD 0.21 billion by 2032, registering a compound annual growth rate of 6.99% over the forecast timeframe. Pennsylvania’s healthcare landscape is defined by two major clinical powerhouses: Philadelphia in the east and Pittsburgh in the west, home to sprawling health systems like Penn Medicine, Jefferson Health, and the University of Pittsburgh Medical Center. Pennsylvania features an older average population, which drives sustained medical-surgical admissions, complex cardiac interventions, and extensive home infusion utilization. Hospital networks across the state heavily prioritize extended-dwell peripheral catheters and polyurethane safety devices to preserve fragile veins and avoid central-line-associated infections in long-stay patients.

Massachusetts constitutes an exceptionally influential medical technology and clinical practice hub, recording USD 0.09 billion in 2026, after recording USD 0.07 billion in 2023, USD 0.08 billion in 2024, and USD 0.08 billion in 2025. The Massachusetts market is projected to reach USD 0.14 billion by 2032, advancing at a compound annual growth rate of 7.64% across the forecast period. The state’s market is centered in Boston, home to Mass General Brigham, Boston Children’s Hospital, and Beth Israel Deaconess Medical Center. These elite teaching institutions serve as primary test sites and national trendsetters for medical device innovation. Massachusetts clinicians actively conduct and publish clinical trials assessing peripheral catheter failure mechanisms, ultrasound-guided vascular placement, and bloodstream infection prevention. Consequently, hospital procurement in Massachusetts is overwhelmingly skewed toward premium, high-tier closed systems, power-injectable catheters, and integrated stabilization technologies backed by rigorous clinical data.

New Jersey represents an essential and densely populated regional market, generating USD 0.08 billion in 2026, having expanded from USD 0.07 billion in 2023, USD 0.07 billion in 2024, and USD 0.08 billion in 2025. The state is forecast to attain USD 0.12 billion by 2032, expanding at a compound annual growth rate of 6.99% over the forecast period. New Jersey’s market is driven by extensive regional health networks such as Hackensack Meridian Health and RWJBarnabas Health, which manage dense networks of acute care hospitals, ambulatory surgery suites, and outpatient infusion clinics. The state exhibits high procedural volumes and stringent infection control compliance oversight, sustaining steady, high-volume procurement of safety-engineered and blood-control peripheral catheters.

The northern New England states of Connecticut, Rhode Island, New Hampshire, Maine, and Vermont collectively accounted for USD 0.05 billion in 2026, following historical performance of USD 0.04 billion in 2023, USD 0.04 billion in 2024, and USD 0.04 billion in 2025. This collective northern corridor is projected to reach USD 0.08 billion by 2032, growing at a compound annual growth rate of 8.14%. While states like Maine, New Hampshire, and Vermont possess smaller, more rural populations, their aging demographics and extensive home healthcare networks create strong, specialized demand for long-lasting, extended-dwell peripheral catheters that support decentralized, out-of-hospital therapy administration.

Midwest

The Midwest represents a highly stable, high-volume manufacturing and healthcare delivery territory, generating USD 0.55 billion in 2026, up from historical benchmarks of USD 0.44 billion in 2023, USD 0.47 billion in 2024, and USD 0.51 billion in 2025. The Midwest market is projected to reach USD 0.83 billion by 2032, advancing at a compound annual growth rate of 7.10% throughout the forecast horizon. The Midwest is characterized by extensive, mature integrated delivery networks, prominent academic medical centers, expansive rural health alliances, and dense community hospital networks. Regional clinical utilization is driven by substantial populations managing chronic lifestyle diseases, including diabetes, hypertension, obesity, and cardiopulmonary disorders. Health systems across the Midwest operate under highly disciplined supply chain architectures, relying heavily on group purchasing organization compliance, standardized clinical protocols, and rigorous total-cost-of-ownership evaluations when awarding multi-year peripheral vascular supply contracts.

Illinois serves as the economic and clinical anchor of the Midwest, generating USD 0.13 billion in 2026, following historical revenue milestones of USD 0.10 billion in 2023, USD 0.11 billion in 2024, and USD 0.12 billion in 2025. The Illinois market is projected to reach USD 0.20 billion by 2032, expanding at a compound annual growth rate of 7.43% across the forecast period. Illinois’s market is dominated by the sprawling Chicago metropolitan healthcare corridor, which includes premier academic systems such as Northwestern Medicine, Rush University Medical Center, and the University of Chicago Medicine, alongside massive community hospital networks like Advocate Health. The Chicago market generates enormous daily procedural volumes across emergency medicine, trauma surgery, and specialized oncology, consuming substantial volumes of safety-engineered peripheral catheters. Furthermore, Illinois health systems are aggressive early adopters of ultrasound-guided peripheral catheterization programs designed to improve first-stick success in emergency triage units.

Ohio represents the second-largest Midwestern state market, accounting for USD 0.11 billion in 2026, having grown from USD 0.09 billion in 2023, USD 0.10 billion in 2024, and USD 0.10 billion in 2025. The state is forecast to attain USD 0.17 billion by 2032, registering a compound annual growth rate of 7.52% over the forecast timeframe. Ohio’s vascular access landscape is anchored by world-class clinical institutions, most notably the Cleveland Clinic, alongside major regional health systems in Columbus, Cincinnati, Dayton, and Toledo. Ohio’s healthcare systems manage large, complex patient populations with significant surgical and cardiovascular care needs. Cleveland Clinic and other regional health networks enforce rigorous, protocolized vascular access standards that prioritize vein preservation, driving widespread clinical adoption of advanced closed-system catheters, blood-control devices, and integrated stabilization technologies.

Michigan constitutes a vital regional market, valued at USD 0.10 billion in 2026, up from historical levels of USD 0.08 billion in 2023, USD 0.08 billion in 2024, and USD 0.09 billion in 2025. The Michigan market is projected to reach USD 0.15 billion by 2032, charting a compound annual growth rate of 6.99% across the forecast period. Demand is anchored by major clinical systems across the Detroit metropolitan corridor, Ann Arbor, and Grand Rapids, including Michigan Medicine, Henry Ford Health, and Corewell Health. These expansive networks maintain high surgical volumes and active emergency departments. Michigan healthcare facilities emphasize occupational safety and nursing efficiency, executing consolidated supply chain agreements that mandate the exclusive deployment of passive safety-engineered catheters to mitigate needlestick risks among clinical staff.

Indiana represents a strategically significant healthcare and life sciences corridor, generating USD 0.06 billion in 2026, following historical performance of USD 0.05 billion in 2023, USD 0.05 billion in 2024, and USD 0.06 billion in 2025. The state is forecast to achieve USD 0.09 billion by 2032, advancing at a compound annual growth rate of 6.99%. Indiana’s market is anchored by Indianapolis-based healthcare networks, including Indiana University Health, Ascension St. Vincent, and Community Health Network. Indiana’s healthcare institutions manage a substantial mix of urban trauma facilities and rural regional hospitals, creating steady, recurring demand for both high-end power-injectable safety catheters and cost-efficient shielded peripheral systems.

Wisconsin accounted for USD 0.05 billion in 2026, having grown from USD 0.04 billion in 2023, USD 0.04 billion in 2024, and USD 0.05 billion in 2025. The Wisconsin market is anticipated to reach USD 0.08 billion by 2032, progressing at a compound annual growth rate of 8.14% over the forecast timeframe. Anchored by major health systems in Milwaukee and Madison, such as Froedtert Health and UW Health, Wisconsin healthcare providers are recognized for high-quality, efficient clinical care delivery. Health networks in Wisconsin place significant emphasis on reducing hospital-acquired conditions, driving progressive transitions toward closed-system intravenous catheters that suppress intraluminal infection risks.

The broader Midwestern territory includes Minnesota, Missouri, Iowa, Kansas, Nebraska, North Dakota, and South Dakota, collectively generating USD 0.10 billion in 2026 and projected to reach USD 0.14 billion by 2032, expanding at a compound annual growth rate of 5.77%. Minnesota stands out within this group as the home of the Mayo Clinic in Rochester, an elite global clinical destination that establishes international best practices in vascular access, vein preservation, and patient comfort. Across the rural plains of Iowa, Kansas, and the Dakotas, regional hospital networks prioritize rugged, easy-to-use safety catheters that provide reliable performance across low-resource community clinics and critical access hospitals.

West

The West represents the fastest-growing and most technologically progressive regional market for peripheral intravenous catheters, generating USD 0.57 billion in 2026, following historical revenue milestones of USD 0.46 billion in 2023, USD 0.49 billion in 2024, and USD 0.53 billion in 2025. The western regional market is forecast to reach USD 0.94 billion by 2032, advancing at a rapid compound annual growth rate of 8.69% across the 2027 through 2032 forecast period. The West’s impressive growth trajectory is propelled by rapid population expansion across the Mountain West and Desert Southwest, widespread expansion of private ambulatory surgery centers, progressive nursing practice standards, and an aggressive appetite for digital healthcare integration and advanced medtech devices. Furthermore, western healthcare networks operate under progressive occupational safety and clinical quality mandates that encourage rapid adoption of premium closed systems, ultrasound-guided vascular access programs, and extended-dwell midline alternatives.

California represents the undisputed commercial giant of the West and the single largest state market for peripheral intravenous catheters in the entire United States. In 2026, the California market was valued at USD 0.32 billion, having expanded from USD 0.25 billion in 2023, USD 0.27 billion in 2024, and USD 0.29 billion in 2025. The state is projected to achieve a market valuation of USD 0.53 billion by 2032, expanding at a rapid compound annual growth rate of 8.78% across the forecast period. California’s market size is driven by its massive population of nearly 40 million residents and an expansive healthcare network comprising hundreds of acute care hospitals, trauma centers, and outpatient procedural clinics. Premier health systems spanning Los Angeles, the San Francisco Bay Area, San Diego, and Sacramento, such as Kaiser Permanente, Sutter Health, UCLA Health, and Stanford Health Care, consume enormous volumes of vascular access devices daily. California was the historical pioneer in enacting stringent state-level occupational sharps safety legislation, which served as the blueprint for federal OSHA mandates. Today, California health systems enforce the nation’s strictest workplace safety and needle-free protocols, driving universal clinical adoption of passive safety catheters, advanced closed blood-control systems, and power-injectable devices.

Washington constitutes the second-largest state market in the Pacific Northwest, generating USD 0.07 billion in 2026, following historical levels of USD 0.05 billion in 2023, USD 0.06 billion in 2024, and USD 0.06 billion in 2025. The Washington market is projected to reach USD 0.12 billion by 2032, advancing at a compound annual growth rate of 9.39% throughout the forecast horizon. Washington’s market is anchored by the Seattle metropolitan corridor, home to world-renowned clinical and research institutions like UW Medicine, Providence Health, and the Fred Hutchinson Cancer Center. Healthcare providers in Washington are recognized for rapid technological adoption, progressive nursing leadership, and strict environmental and clinical quality standards. Regional health networks aggressively deploy ultrasound-guided vascular access workflows and integrated closed catheters to maximize first-stick success, reduce disposable medical waste, and protect patient vessel health across both acute inpatient wards and ambulatory oncology suites.

Arizona represents an exceptionally fast-growing state market in the Southwest, recording USD 0.06 billion in 2026, up from USD 0.05 billion in 2023, USD 0.05 billion in 2024, and USD 0.06 billion in 2025. The Arizona market is forecast to achieve USD 0.11 billion by 2032, expanding at a rapid compound annual growth rate of 10.63% over the forecast timeframe. Arizona’s rapid market expansion is fueled by massive demographic in-migration, rapid suburban development across the Phoenix and Tucson metropolitan areas, and a rapidly expanding retiree population. Older adults across Arizona generate high daily clinical demand for surgical procedures, emergency interventions, and long-term infusion therapies. Arizona hospital systems, including Banner Health and HonorHealth, are heavily expanding their procedural capacity, constructing new ambulatory surgery suites, and procuring specialized polyurethane and extended-dwell catheters engineered to successfully manage fragile, difficult-to-cannulate peripheral veins.

Colorado represents a highly dynamic and expanding Mountain West market, valued at USD 0.05 billion in 2026, following historical revenues of USD 0.04 billion in 2023, USD 0.04 billion in 2024, and USD 0.05 billion in 2025. The Colorado market is anticipated to reach USD 0.09 billion by 2032, growing at a compound annual growth rate of 10.29% over the forecast period. Anchored by the Denver-Aurora-Boulder healthcare corridor, Colorado is home to major integrated networks such as UCHealth and Centura Health. The state features an active, health-conscious population alongside rapid urban population growth, driving significant investments in sports medicine clinics, ambulatory surgical centers, and modern acute care facilities. Colorado health systems prioritize high-efficiency, premium medical consumables, supporting strong clinical penetration of blood-control safety catheters and integrated securement systems.

The remainder of the western region spans Oregon, Utah, Nevada, Idaho, New Mexico, Hawaii, Alaska, Montana, and Wyoming, collectively accounting for USD 0.07 billion in 2026 and forecast to reach USD 0.09 billion by 2032, reflecting a compound annual growth rate of 4.28%. Utah and Nevada represent notable high-growth nodes within this group, driven by explosive population growth across Salt Lake City and Las Vegas. Conversely, vast rural territories across Montana, Wyoming, and Alaska rely on specialized regional critical-access hospitals and aeromedical transport services, which require rugged, fail-safe safety catheters and rapid-placement vascular devices capable of performing reliably under harsh pre-hospital conditions.

Key Market Players

The U.S. Peripheral Intravenous Catheters competitive landscape is highly consolidated around a core cadre of multinational medical technology corporations, complemented by focused vascular access innovators and specialized consumable manufacturers.

The primary market participants operating within the U.S. peripheral intravenous catheters industry include:

Becton, Dickinson and Company
B. Braun SE / B. Braun Medical Inc.
Smiths Medical / ICU Medical, Inc.
Teleflex Incorporated
Terumo Corporation / Terumo Medical Corporation
Argon Medical Devices, Inc.
Nipro Medical Corporation
Medical Components, Inc. (Medcomp)
Cook Medical LLC
Vygon SA
Greiner Bio-One International GmbH
Retractable Technologies, Inc.
Access Scientific, LLC / AccuCath
Vascular Pathways / C. R. Bard / BD
Delta Med S.p.A.

Becton, Dickinson and Company maintains the preeminent leadership position within the U.S. peripheral intravenous catheter marketplace, anchored by its universally recognized brands including BD Insyte, BD Autoguard, BD Nexiva, and the BD BaroCath portfolio. BD commands immense market share across acute care hospitals, health systems, and alternate-site facilities through its pioneering safety architectures, such as the Instaflash needle notch technology and fully closed system platforms. BD’s commercial strength is fortified by deep group purchasing organization contracts, vast manufacturing and distribution economies of scale, and an all-encompassing vascular access management strategy that packages peripheral catheters alongside needle-free connectors, vascular visualization ultrasound platforms, and catheter stabilization systems.

B. Braun Medical Inc. represents another foundational powerhouse across the U.S. landscape, celebrated for its premium Introcan Safety and Introcan Safety 2 product portfolios. B. Braun has driven widespread clinical conversion toward passive, fully automated safety engineering, eliminating user activation steps to protect healthcare personnel from needlestick trauma. B. Braun has heavily advanced the commercialization of blood-control technology with its multi-access blood-control septum platforms, which keep the catheter hub sealed through multiple connections. B. Braun’s clinical emphasis on passive safety automation, coupled with robust domestic manufacturing facilities and strong enterprise health system distribution agreements, positions the company as a top-tier contender across inpatient and ambulatory surgical sectors.

ICU Medical, Inc., having completed the transformative acquisition of Smiths Medical and its flagship Jelco brand family, represents an imposing force across domestic peripheral vascular access. The Jelco portfolio, encompassing legendary brands such as Jelco, Jelco Optiva, and ViaValve, provides ICU Medical with an enormous installed base across both acute hospitals and decentralized outpatient clinics. ICU Medical leverages the ViaValve safety catheter’s advanced blood-control technology to capture clinical share, while cross-selling these access devices alongside its expansive fluid therapy, infusion pump, and vascular consumable ecosystems, delivering comprehensive vascular solutions to value analysis committees nationwide.

Teleflex Incorporated occupies a strategically vital position at the high-acuity end of the vascular access continuum, driven by its prestigious Arrow brand portfolio. While historically dominating central venous access, Teleflex has captured valuable peripheral market share through its specialized line of Arrow extended-dwell peripheral catheters and short midline systems. Teleflex focuses heavily on the clinical challenge of difficult intravenous access, engineering long, ultrasound-guided polyurethane catheters that bridge the gap between standard peripheral lines and peripherally inserted central catheters. By empowering vascular access teams to achieve deep-vein peripheral access under ultrasound guidance, Teleflex enables health systems to reduce unnecessary central line insertions, mitigate bloodstream infection risks, and lower procedural costs.

Terumo Medical Corporation maintains an established and respected commercial footprint across the United States, anchored by its Surflo and Surshield product lines. Terumo is recognized for its proprietary needle-grinding and polishing technologies, which produce ultra-sharp, finely beveled needles that achieve smooth, low-drag dermal and vascular penetration with minimal patient discomfort. Terumo’s Surshield safety catheters utilize reliable, locking hinged shields that allow clinicians to secure contaminated sharps smoothly without altering standard venipuncture techniques, making them popular across cost-conscious hospital networks, blood collection centers, and high-throughput outpatient procedural facilities.

Argon Medical Devices, Inc. focuses on specialized vascular access and interventional devices, providing high-reliability catheter lines, introducers, and guidewire-assisted vascular access kits designed for complex clinical environments. Nipro Medical Corporation competes across hospital consumables and renal care, offering high-precision safety peripheral catheters and introducers characterized by consistent needle sharpness, smooth siliconization, and competitive unit pricing. Medical Components, Inc., operating as Medcomp, specializes in advanced vascular access catheters, engineering extended-dwell polyurethane peripheral lines and midline devices designed to maintain high-flow vascular access across long-term inpatient and outpatient parenteral infusion regimens.

Cook Medical LLC maintains specialized relevance through its extensive interventional portfolio, producing ultra-reliable vascular access sheaths, micropuncture introducer sets, and specialized peripheral catheters utilized in complicated vascular access, trauma, and pediatric interventions. Vygon SA delivers high-precision neonatal and pediatric vascular access devices, engineering specialized ultra-fine catheters that satisfy the exacting demands of neonatal intensive care units. Greiner Bio-One International GmbH provides high-quality safety intravenous cannulas and blood collection access systems, leveraging automated manufacturing excellence. Retractable Technologies, Inc. competes on active safety innovation, deploying its proprietary automated spring-retraction engineering across safety IV catheters under the VanishPoint brand name. Access Scientific, LLC, known for the AccuCath platform, revolutionized the extended-dwell space with integrated coiled-wire guidewire catheters that eradicate catheter kinking during difficult peripheral placements. Delta Med S.p.A. rounds out the competitive landscape by supplying specialized safety catheters and closed-system components through flexible contract manufacturing and private-label partnerships.

Recent Developments

The U.S. peripheral intravenous catheter landscape has experienced significant regulatory, clinical, and competitive evolution since 2024, characterized by strategic supply chain restructuring, updated clinical practice guidelines, and continuous technological clearances from the U.S. Food and Drug Administration.

A foundational regulatory milestone shaping the commercial environment was the comprehensive update to the Infusion Nurses Society Infusion Therapy Standards of Practice. The revised standards formally discouraged the historical practice of routinely replacing peripheral intravenous catheters every 72 to 96 hours, reinforcing that peripheral catheters should remain in place until intravenous therapy is completed unless a specific clinical complication emerges. The standards also elevated recommendations surrounding the immediate deployment of ultrasound guidance and specialized long-peripheral or extended-dwell catheters for patients exhibiting markers of difficult intravenous access. This guidance has profoundly altered hospital purchasing behavior, moving procurement committees away from ordering cheap commodity catheters for continuous replacement cycles and toward purchasing premium polyurethane closed systems and extended-dwell devices designed to safely dwell for multiple weeks.

Supply chain resilience and domestic manufacturing security have emerged as urgent strategic priorities across U.S. healthcare systems. In late 2024, severe climatic disruptions and logistical bottlenecks highlighted the acute vulnerability of offshore medical device supply chains, which had historically caused widespread shortages of intravenous fluids and critical vascular consumables. In response, major integrated delivery networks and federal health authorities have enacted strict supply diversification mandates. Market leaders such as Becton Dickinson and B. Braun Medical have accelerated capital investments into their North American manufacturing plants, expanding automated extrusion lines, cleanroom assembly operations, and localized distribution hubs to guarantee uninterrupted domestic supply of sterile peripheral catheters during global supply shocks.

Food and Drug Administration 510(k) clearances across 2025 and 2026 have demonstrated intense manufacturing focus on closed-system fluid control and integrated needle-free safety engineering. Becton Dickinson secured regulatory clearances expanding the indications of its advanced closed-catheter portfolios, incorporating enhanced dual-pathway blood control septums and validated compatibility with automated high-pressure power injectors. Similarly, B. Braun Medical advanced its Introcan Safety 2 platform, receiving updated clearances for multi-use blood containment mechanisms that eliminate blood exposure across repeated syringe and administration set connections, addressing both occupational biohazard mitigation and intraluminal infection suppression.

Mergers, acquisitions, and portfolio integrations have reshaped corporate competition across the vascular access terrain. The strategic integration of Smiths Medical into ICU Medical’s corporate framework reached operational maturity, enabling ICU Medical to unify the legacy Jelco peripheral catheter brand with its broad portfolio of needle-free connectors, specialized extension sets, and smart infusion pumps. This consolidated footprint allows ICU Medical to aggressively challenge Becton Dickinson in enterprise-wide tender bids by offering end-to-end vascular infusion bundles under unified group purchasing agreements.

Simultaneously, the integration of portable point-of-care ultrasound visualization into standard peripheral catheterization workflows has accelerated. Handheld, wireless ultrasound probes paired with mobile tablet software are becoming standard equipment on nursing floors, emergency departments, and dedicated vascular access teams. Recognizing this clinical paradigm shift, catheter manufacturers are increasingly engineering echogenic peripheral catheters. These specialized catheters feature microscopic surface dimpling, laser texturing, or embedded metallic markers near the catheter tip that reflect ultrasonic waves directly back to the probe, providing clear, real-time visualization of the catheter tip as it enters deep, non-palpable veins. This technological symbiosis between ultrasound hardware and echogenic catheter consumables is dramatically elevating first-stick insertion success rates in difficult access populations and driving rapid clinical adoption across major trauma networks nationwide.

Conclusion

The U.S. Peripheral Intravenous Catheters Market is positioned for robust, sustained expansion, rising from USD 2.75 billion in 2026 to reach USD 4.31 billion by 2032, propelled by a compound annual growth rate of 7.80% from 2027 through 2032. The historical development of the market, moving from USD 2.20 billion in 2023 to USD 2.55 billion in 2025, reflects the normalization of acute surgical and inpatient admission volumes, reinforced by the structural institutional transition toward premium safety-engineered and closed-system vascular access devices.

The underlying growth thesis for peripheral intravenous catheters extends far beyond simple demographic aging and rising procedural counts. The market is undergoing a structural paradigm shift in how vascular access is conceptualized, procured, and executed across the American healthcare enterprise. The historical era of viewing peripheral intravenous catheters as commoditized, disposable plastic cannulas subjected to routine 72-hour replacement cycles has permanently ended. Driven by value-based clinical quality metrics, acute nursing shortages, strict occupational safety regulations, and authoritative evidence-based clinical guidelines, U.S. healthcare providers are aggressively transitioning toward integrated vessel health and preservation models.

The most lucrative and commercially viable growth avenues through 2032 will center on integrated closed-system safety catheters, extended-dwell midline alternatives, multi-use blood-control septum technologies, echogenic catheters engineered for ultrasound guidance, and advanced thermo-softening polyurethane biomaterials. Integrated closed catheters represent an exceptionally high-growth product class, as health systems seek all-in-one pre-assembled devices that prevent biohazardous blood exposure, isolate the vascular insertion site from mechanical disruption, and eliminate catheter manipulation-induced phlebitis. Similarly, extended-dwell peripheral catheters are capturing substantial market share from expensive, invasive central venous lines, delivering safe, multi-week vascular access for intermediate inpatient and home infusion regimens at a fraction of the procedural cost and infection risk.

From an end-user perspective, hospitals and integrated delivery networks will continue to anchor the vast majority of overall market value, utilizing peripheral catheters across high-volume emergency triage, perioperative suites, and acute inpatient floors. However, ambulatory surgery centers and home infusion therapy environments will represent the fastest-expanding procedural channels, fueled by the accelerating outpatient migration of complex elective surgeries, cancer chemotherapies, and specialized biologic infusions. In these decentralized environments, reliable first-stick success, low complication rates, and prolonged catheter dwell times are essential to prevent disruptive, costly emergency hospital transfers.

Geographically, commercial opportunity will remain heavily concentrated across the South, which commands the nation’s largest regional revenue pool driven by rapid population growth, high surgical densities, and massive Medicare populations across Florida and Texas. The West will maintain its position as the fastest-growing territory, powered by California’s massive healthcare economy, progressive workplace safety mandates, and rapid adoption of advanced closed vascular technologies. The Northeast will continue to serve as the nation’s premier high-value epicenter for evidence-based clinical practice and premium technology evaluation, while the Midwest offers massive, recurring revenue opportunities anchored by disciplined integrated delivery networks standardizing vascular access across expansive hospital networks.

For medical device manufacturers, clinical executives, supply chain strategists, and healthcare investors, competitive leadership through 2032 will belong to enterprises that look beyond the mechanical needle point and address the entire peripheral vascular pathway. Success requires delivering integrated, clinically validated ecosystems that combine automated passive sharps safety, zero-exposure blood containment, superior hemocompatible materials, integrated engineered securement, and dedicated clinical education. Companies that master this comprehensive, value-driven clinical approach will successfully insulate their enterprise contracts, capture market share from commoditized competitors, and drive superior clinical and economic outcomes across the American healthcare delivery landscape.